Alok Srivastava

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/15611/publications.pdf

Version: 2024-02-01

322 papers	9,983 citations	71102 41 h-index	42399 92 g-index
332 all docs	332 docs citations	332 times ranked	7577 citing authors

#	Article	IF	Citations
1	Guidelines for the management of hemophilia. Haemophilia, 2013, 19, e1-47.	2.1	1,538
2	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis and Haemostasis, 2006, 4, 2103-2114.	3.8	1,061
3	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	2.1	915
4	Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1935-1939.	3.8	530
5	Impact, Diagnosis and Treatment of von Willebrand Disease. Thrombosis and Haemostasis, 2000, 84, 160-174.	3.4	478
6	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis, 2005, 3, 2619-2626.	3.8	317
7	New ISSCR Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research. Cell Stem Cell, 2008, 3, 607-609.	11.1	218
8	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood, 2004, 104, 1574-1577.	1.4	155
9	Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regenerative Medicine, 2018, 13, 859-866.	1.7	147
10	Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia, 2006, 12, 82-89.	2.1	123
11	Diagnostic Accuracy of Ultrasound for Assessment of Hemophilic Arthropathy: MRI Correlation. American Journal of Roentgenology, 2015, 204, W336-W347.	2.2	98
12	Acute myeloid leukaemia: challenges and real world data from India. British Journal of Haematology, 2015, 170, 110-117.	2.5	96
13	Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells, Molecules, and Diseases, 2003, 30, 264-270.	1.4	95
14	Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia, 2005, 11, 598-602.	2.1	92
15	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	3.5	87
16	SARS-2 Coronavirusâ€“Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?. Seminars in Thrombosis and Hemostasis, 2020, 46, 777-780.	2.7	85
17	Comprehensive care for haemophilia around the world. Haemophilia, 2004, 10, 9-13.	2.1	83
18	Improved Clinical Outcomes of High Risk Î² Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. PLoS ONE, 2013, 8, e61637.	2.5	78

#	Article	IF	Citations
19	A study of reported factor VIII use around the world. Haemophilia, 2010, 16, 33-46.	2.1	75
20	Tests of global haemostasis and their applications in bleeding disorders. Haemophilia, 2010, 16, 85-92.	2.1	75
21	Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia, 2005, 11, 481-491.	2.1	69
22	A New Stratification Strategy That Identifies a Subset of Class III Patients with an Adverse Prognosis among Children with Î² Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 889-894.	2.0	67
23	Psychometric analysis of the Functional Independence Score in Haemophilia (FISH). Haemophilia, 2007, 13, 620-626.	2.1	65
24	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia, 2017, 23, 11-24.	2.1	63
25	Molecular Characterization of a Multiethnic Group of 21 Patients with Type 3 von Willebrand Disease. Thrombosis and Haemostasis, 2000, 84, 536-540.	3.4	61
26	The Phenotypic Heterogeneity of Severe Hemophilia. Seminars in Thrombosis and Hemostasis, 2008, 34, 128-141.	2.7	61
27	Nuclear factor (NF)â€ÎºB and its associated pathways are major molecular regulators of bloodâ€induced joint damage in a murine model of hemophilia. Journal of Thrombosis and Haemostasis, 2013, 11, 293-306.	3.8	61
28	Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia â€“ the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplantation, 2005, 36, 839-845.	2.4	60
29	Cure for thalassemia major â€“ from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica, 2017, 102, 214-223.	3.5	57
30	Molecular mechanisms underlying hemophilia A phenotype in seven females. Journal of Thrombosis and Haemostasis, 2009, 7, 976-982.	3.8	56
31	Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children. Annals of Hematology, 2016, 95, 1429-1434.	1.8	56
32	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1105-1109.	3.8	54
33	Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain. Blood, 2008, 112, 5026-5026.	1.4	53
34	Laboratory issues in bleeding disorders. Haemophilia, 2006, 12, 68-75.	2.1	51
35	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51
36	Long-Term Cultured Human Term Placenta-Derived Mesenchymal Stem Cells of Maternal Origin Displays Plasticity. Stem Cells International, 2012, 2012, 1-11.	2.5	50

#	Article	IF	Citations
37	Management of haemophilia in the developing world. Haemophilia, 1998, 4, 474-480.	2.1	48
38	Dose and response in haemophilia â€“ optimization of factor replacement therapy. British Journal of Haematology, 2004, 127, 12-25.	2.5	46
39	Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy, 2015, 17, 1663-1666.	0.7	44
40	Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia, 2016, 22, 925-933.	2.1	44
41	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	2.7	43
42	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. PLoS ONE, 2015, 10, e0121912.	2.5	43
43	RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics, 2015, 16, 877-890.	1.3	41
44	Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A. Human Gene Therapy, 2018, 29, 1183-1201.	2.7	39
45	Epidemiology of von Willebrand Disease in Developing Countries. Seminars in Thrombosis and Hemostasis, 2005, 31, 569-576.	2.7	38
46	Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-Î± pathway. Blood, 2018, 132, 1064-1074.	1.4	38
47	Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor <scp>VIII</scp> Fc fusion protein. Haemophilia, 2018, 24, 77-84.	2.1	37
48	Informativeness of linkage analysis for genetic diagnosis of haemophilia A in India. Haemophilia, 2004, 10, 553-559.	2.1	36
49	Delivery of haemophilia care in the developing world. Haemophilia, 1998, 4, 33-40.	2.1	34
50	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood, 2021, 137, 556-568.	1.4	34
51	Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia. Haemophilia, 1998, 4, 799-801.	2.1	33
52	High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. Biomedical Applications, 1999, 721, 147-152.	1.7	33
53	Part 1: Defining unproven cellular therapies. Cytotherapy, 2016, 18, 117-119.	0.7	33
54	Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis, 2018, 16, 253-261.	3.8	33

#	Article	IF	Citations
55	Factor replacement therapy in haemophilia - are there models for developing countries?. Haemophilia, 2003, 9, 391-396.	2.1	32
56	Blood-Induced Arthropathy in Hemophilia: Mechanisms and Heterogeneity. Seminars in Thrombosis and Hemostasis, 2015, 41, 832-837.	2.7	31
57	Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophiliaâ€specific instruments. Haemophilia, 2019, 25, e1-e10.	2.1	31
58	Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1999, 24, 5-11.	2.4	30
59	Definitions in Hemophilia: Resolved and Unresolved Issues. Seminars in Thrombosis and Hemostasis, 2015, 41, 819-825.	2.7	30
60	Frequency of rare <scp>BCR</scp>â€<scp>ABL</scp>1 fusion transcripts in chronic myeloid leukemia patients. International Journal of Laboratory Hematology, 2017, 39, 235-242.	1.3	30
61	Hemophilia Treatment in Developing Countries: Products and Protocols. Seminars in Thrombosis and Hemostasis, 2005, 31, 495-500.	2.7	29
62	Efficacy and safety of a <scp>VWF</scp>/<scp>FVIII</scp> concentrate (wilate^{Â®}) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia, 2017, 23, 264-272.	2.1	29
63	Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin. ELife, 2022, 11, .	6.0	29
64	Role of Molecular Genetics in Hemophilia: From Diagnosis to Therapy. Seminars in Thrombosis and Hemostasis, 2012, 38, 64-78.	2.7	28
65	Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia, 2016, 30, 2169-2178.	7.2	28
66	Developing an algorithm of informative markers for evaluation of chimerism after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 2006, 37, 751-755.	2.4	27
67	Clinical Profile and Outcomes of Patients with Î² Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant. Blood, 2012, 120, 4160-4160.	1.4	27
68	Invasive fungal infection following chemotherapy for acute myeloid leukaemiaâ€"Experience from a developing country. Mycoses, 2017, 60, 686-691.	4.0	26
69	Surgery for Hemophilia in Developing Countries. Seminars in Thrombosis and Hemostasis, 2005, 31, 538-543.	2.7	25
70	Inflammation is key to hemophilic arthropathy. Blood, 2015, 126, 2175-2176.	1.4	25
71	Assessments of outcome in haemophilia â€“ what is the added value of <scp>QoL</scp> tools?. Haemophilia, 2015, 21, 430-435.	2.1	25
72	Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide. Bone Marrow Transplantation, 2018, 53, 169-174.	2.4	25

#	Article	IF	Citations
73	Factor concentrates for haemophilia in the developing world. Haemophilia, 1998, 4, 481-485.	2.1	24
74	ATP-binding casette transporter expression in acute myeloid leukemia: association within vitrocytotoxicity and prognostic markers. Pharmacogenomics, 2017, 18, 235-244.	1.3	24
75	Emerging therapies for haemophilia â€•Global perspective. Haemophilia, 2018, 24, 15-21.	2.1	24
76	Factor replacement for haemophilia - should cryoprecipitate be used?. Haemophilia, 1999, 5, 301-305.	2.1	23
77	A study of reported factor IX use around the world. Haemophilia, 2011, 17, 446-455.	2.1	23
78	Sensitivity and Robustness of Spatially Dependent Thrombin Generation and Fibrin Clot Propagation. Biophysical Journal, 2018, 115, 2461-2473.	0.5	23
79	Allogeneic Stem Cell Transplantation for Thalassemia Major. Hematology/Oncology Clinics of North America, 2014, 28, 1187-1200.	2.2	22
80	Systematic evaluation of markers used for the identification of human induced pluripotent stem cells. Biology Open, 2017, 6, 100-108.	1.2	22
81	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Pharmacology and Therapeutics, 2018, 104, 575-583.	4.7	22
82	Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 494-500.	2.0	22
83	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biology of Blood and Marrow Transplantation, 2019, 25, 2330-2337.	2.0	22
84	Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia, 2001, 7, 117-122.	2.1	22
85	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia, 2018, 24, e33-e49.	2.1	21
86	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 2019, 25, 2322-2329.	2.0	21
87	Arsenic Trioxide (As2O3) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome.. Blood, 2004, 104, 889-889.	1.4	21
88	Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cytotherapy, 2022, 24, 686-690.	0.7	21
89	Polymyositis - an unusual manifestation of chronic graft-versus-host disease. Rheumatology International, 2001, 20, 169-170.	3.0	20
90	Management of Hemophilia in Patients with Inhibitors: The Perspective from Developing Countries. Seminars in Thrombosis and Hemostasis, 2009, 35, 820-826.	2.7	20

#	Article	IF	Citations
91	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 78, 1051-1058.	2.3	20
92	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
93	Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage â€“ the <scp>MUSFIH</scp> study. Haemophilia, 2017, 23, 538-546.	2.1	20
94	Dose and outcome of care in haemophilia - how do we define cost-effectiveness?. Haemophilia, 2004, 10, 216-220.	2.1	19
95	Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with Î² Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic Bone Marrow Transplant. Biology of Blood and Marrow Transplantation, 2009, 15, 597-609.	2.0	19
96	Factor VIII/factor IX prophylaxis for severe hemophilia. Seminars in Hematology, 2016, 53, 3-9.	3.4	19
97	Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. Journal of Global Oncology, 2019, 5, 1-13.	0.5	19
98	Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. Human Gene Therapy, 2020, 31, 1114-1123.	2.7	19
99	Fracture neck of femur in haemophilia A ? experience from a cohort of 11 patients from a tertiary centre in India. Haemophilia, 2007, 13, 391-394.	2.1	18
100	Impact of pretransplant splenectomy on patients with Î²â€thalassemia major undergoing a matchedâ€related allogeneic stem cell transplantation. Pediatric Transplantation, 2009, 13, 171-176.	1.0	18
101	Differences between developed and developing countries in paediatric care in haemophilia. Haemophilia, 2012, 18, 94-100.	2.1	18
102	Haemophilia care â€“ beyond the treatment guidelines. Haemophilia, 2014, 20, 4-10.	2.1	18
103	Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, e31-e35.	2.0	18
104	External fixators in haemophilia. Haemophilia, 2004, 10, 52-57.	2.1	17
105	External Quality Assessment Scheme for Hemostasis in India. Seminars in Thrombosis and Hemostasis, 2007, 33, 265-272.	2.7	17
106	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 7-16.	0.9	17
107	von Willebrand disease in the developing world. Seminars in Hematology, 2005, 42, 36-41.	3.4	16
108	Achieving and maintaining quality in the laboratory. Haemophilia, 2006, 12, 61-67.	2.1	16

#	Article	IF	Citations
109	Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Bone Marrow Transplantation, 2012, 47, 1178-1185.	2.4	15
110	Advancing Stem Cell Biology toward Stem Cell Therapeutics. Cell Stem Cell, 2012, 10, 149-150.	11.1	15
111	Principles of haemophilia care: The Asiaâ€Pacific perspective. Haemophilia, 2018, 24, 366-375.	2.1	15
112	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	2.1	15
113	Association betweenCYP1A2gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatrica, 2013, 25, 2-11.	2.1	14
114	Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. Frontiers in Immunology, 2018, 9, 1357.	4.8	14
115	Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study. Clinical and Experimental Dermatology, 2019, 44, 161-168.	1.3	14
116	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 131-142.	0.9	14
117	Comparison of Human Platelet Lysate versus Fetal Bovine Serum for Expansion of Human Articular Cartilageâ€“Derived Chondroprogenitors. Cartilage, 2021, 13, 107S-116S.	2.7	14
118	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	2.3	14
119	Management of COVIDâ€19â€associated coagulopathy in persons with haemophilia. Haemophilia, 2021, 27, 41-48.	2.1	14
120	Endothelial cells do not express GSTA1: potential relevance to busulfanâ€mediated endothelial damage during haematopoietic stem cell transplantation. European Journal of Haematology, 2008, 80, 299-302.	2.2	13
121	Diagnosis and Management of<scp>v</scp>on Willebrand Disease: A Developing Country Perspective. Seminars in Thrombosis and Hemostasis, 2011, 37, 587-594.	2.7	13
122	World bleeding disorders registry: The pilot study. Haemophilia, 2018, 24, e113-e116.	2.1	13
123	Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India. Human Gene Therapy, 2021, 32, 451-457.	2.7	12
124	NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance. Blood, 2013, 122, 1455-1455.	1.4	12
125	Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI). Blood, 2021, 138, 4-4.	1.4	12
126	Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). Blood, 2021, 138, LBA-3-LBA-3.	1.4	12

#	Article	IF	Citations
127	Low-dose activated factor IX complex concentrates (FEIBAR) for post-operative haemostasis in a patient with high responding factor VIII inhibitors. Haemophilia, 1995, 1, 274-276.	2.1	11
128	Drugâ€resistant organisms are common in fecal surveillance cultures, predict bacteremia and correlate with poorer outcomes in patients undergoing allogeneic stem cell transplants. Transplant Infectious Disease, 2020, 22, e13273.	1.7	11
129	Risk Stratification without a Liver Biopsy of Patients with Î² Thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant.. Blood, 2009, 114, 659-659.	1.4	11
130	A patient-prioritized ability assessment in haemophilia: the Canadian Occupational Performance Measure. Haemophilia, 2011, 17, 605-611.	2.1	10
131	Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantationâ€"A Single Centre Experience. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 215-222.	0.6	10
132	A new and simplified comprehensive ultrasound protocol of haemophilic joints: the Universal Simplified Ultrasound (US-US) protocol. Clinical Radiology, 2019, 74, 897.e9-897.e16.	1.1	10
133	Prognostic plasma biomarkers of early complications and graftâ€versusâ€host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. EJHaem, 2020, 1, 219-229.	1.0	10
134	Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 652-658.	2.3	10
135	Diagnosis of haemophilia and other inherited bleeding disorders â€•Is a new paradigm needed?. Haemophilia, 2021, 27, 14-20.	2.1	10
136	Direct Generation of Immortalized Erythroid Progenitor Cell Lines from Peripheral Blood Mononuclear Cells. Cells, 2021, 10, 523.	4.1	10
137	Surgery in patients with congenital coagulation disorders. The National Medical Journal of India, 1994, 7, 8-12.	0.3	10
138	Generation of an induced pluripotent stem cell line that mimics the disease phenotypes from a patient with Fanconi anemia by conditional complementation. Stem Cell Research, 2017, 20, 54-57.	0.7	9
139	Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2018, 24, 103-108.	2.0	9
140	Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. Haemophilia, 2019, 25, 67-74.	2.1	9
141	Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. Scientific Reports, 2020, 10, 20640.	3.3	9
142	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	2.1	9
143	The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 126-134.	0.9	8
144	Typeâ€3 von Willebrand disease in Indiaâ€"Clinical spectrum and molecular profile. Haemophilia, 2018, 24, 930-940.	2.1	8

#	Article	IF	Citations
145	Dendritic Cell Type 2 Counts on Day 28 in HLA-Matched Related Allogeneic PBSCT Predicts the Incidence of Acute and Chronic GVHD.. Blood, 2006, 108, 2893-2893.	1.4	8
146	Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance. Blood, 2012, 120, 1390-1390.	1.4	8
147	Haemophilia gene therapyâ€"Update on new country initiatives. Haemophilia, 2022, 28, 61-67.	2.1	8
148	A new multiplex PCR and conformation-sensitive gel electrophoresis strategy for mutation detection in the platelet glycoprotein Î±IIb and Î²3 genes. Journal of Thrombosis and Haemostasis, 2007, 5, 206-209.	3.8	7
149	Standardizing patient outcomes measurement to improve haemophilia care. Haemophilia, 2016, 22, 651-653.	2.1	7
150	Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Blood Cells, Molecules, and Diseases, 2017, 66, 37-46.	1.4	7
151	Allogeneic stem cell transplantation for thalassemia major in India. Pediatric Hematology Oncology Journal, 2017, 2, 114-120.	0.1	7
152	Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions. Transfusion Medicine, 2018, 28, 392-397.	1.1	7
153	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 71-77.	0.6	7
154	Limited utility of plasma elafin as a biomarker for skin graftâ€versusâ€host disease following allogeneic stem cell transplantation. Clinical and Experimental Dermatology, 2021, 46, 1482-1487.	1.3	7
155	Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette. Molecular Therapy - Methods and Clinical Development, 2021, 23, 98-107.	4.1	7
156	Acute Myeloid Leukemia: Challenges and Real World Data from India. Blood, 2014, 124, 3685-3685.	1.4	7
157	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
158	Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.. Blood, 2007, 110, 2880-2880.	1.4	7
159	Part 2: Making the â€œunprovenâ€•â€œprovenâ€• Cytotherapy, 2016, 18, 120-123.	0.7	6
160	Efficacy of narrow band UVB in the treatment of cutaneous GvHD: an Indian experience. Bone Marrow Transplantation, 2016, 51, 988-990.	2.4	6
161	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. Biology of Blood and Marrow Transplantation, 2017, 23, 1815-1816.	2.0	6
162	Generation of an integration-free iPSC line (CSCRi005-A) from erythroid progenitor cells of a healthy Indian male individual. Stem Cell Research, 2018, 29, 148-151.	0.7	6

#	Article	IF	Citations
163	Lack of grading agreement among international hemostasis external quality assessment programs. Blood Coagulation and Fibrinolysis, 2018, 29, 111-119.	1.0	6
164	A Low Incidence of Cytomegalo Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation Despite a High Seroprevalence. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 636-642.	0.6	6
165	Challenges in managing graft-versus-host disease in developing countries: a perspective. Bone Marrow Transplantation, 2019, 54, 641-647.	2.4	6
166	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
167	Six Novel Mutations Including Triple Heterozygosity for Phe31Ser, 514delT and 516Tâ†'G Mutations in Factor X Gene Is Responsible for Congenital Factor X Deficiency in Patients of Indian and Nepali Origin.. Blood, 2004, 104, 1042-1042.	1.4	6
168	Prenatal diagnosis of Glanzmann thrombasthenia. The National Medical Journal of India, 2003, 16, 207-8.	0.3	6
169	Hb Showa-Yakushiji [Î²110(G12)Leuâ†'Pro] in Four Unrelated Patients from West Bengal. Hemoglobin, 2005, 29, 19-25.	0.8	5
170	Cryotherapy for acute haemarthrosis in haemophilia â€“ attempts to understand the â€˜ice ageâ€™ practice. Haemophilia, 2015, 21, e103-5.	2.1	5
171	Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. British Journal of Radiology, 2016, 89, 20151064.	2.2	5
172	AtypicalBCR-ABL1fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. Leukemia and Lymphoma, 2016, 57, 2481-2484.	1.3	5
173	Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 977-983.	2.4	5
174	Management of Hemophilic Cysts and Pseudotumors ofÂthe Hand in Bleeding Disorders: A Case Series. Journal of Hand Surgery, 2018, 43, 486.e1-486.e9.	1.6	5
175	Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD). Indian Journal of Hematology and Blood Transfusion, 2019, 35, 223-232.	0.6	5
176	Ultrasound and magnetic resonance imaging for the detection of blood: An exâ€vivo study. Haemophilia, 2021, 27, 488-493.	2.1	5
177	Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Rituximab in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP (Rituximab, Cyclophosphamide, Adriamycin,) Tj ETQq1 1 0.784314 rgBT		
178	Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. Indian Journal of Medical Research, 2018, 147, 464.	1.0	5
179	Ediatric Hyperfibrotic Myelodysplasia: An Unusual Clinicopathologic Entity. Pediatric Hematology and Oncology, 1997, 14, 133-139.	0.8	4
180	Linking the world with training and research for improving haemophilia care. Haemophilia, 2008, 14, 43-48.	2.1	4

#	Article	IF	Citations
181	Clinical, Hematological and Molecular Analysis of Homozygous Hb E (HBB: c.79Gâ€‰>â€‰A) in the Indian Population. Hemoglobin, 2016, 40, 16-19.	0.8	4
182	Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Cellular Immunology, 2018, 325, 64-68.	3.0	4
183	Performance of an In-House Real-Time PCR Assay for Detecting Cytomegalovirus Infection among Transplant Patients from a Tertiary Care Centre. Indian Journal of Medical Microbiology, 2018, 36, 241-246.	0.8	4
184	Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 43-49.	0.6	4
185	Higher Incidence of Graft Rejection in Non-Sibling Fully Matched Related Donor Stem Cell Transplants for Thalassemia Major: A Cautionary Note. Blood, 2018, 132, 2178-2178.	1.4	4
186	Three Separate Glanzmann Thrombasthenia Mutants Affecting the Î±IIb Î²-Propeller Result in Production of Normally Stable Pro-Î±IIb, but Impaired Progression from Endoplasmic Reticulum to Golgi.. Blood, 2004, 104, 741-741.	1.4	4
187	Bone Marrow-Derived Mesenchymal Stem Cells Augment Regeneration of Intervertebral Disc in a Reproducible and Validated Mouse Intervertebral Disc Degeneration Model. Neurology India, 2021, 69, 1565.	0.4	4
188	Optimizing clotting factor replacement therapy in hemophilia: A global need. Hematology, 2005, 10, 229-230.	1.5	3
189	Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India â€“ response to Gupta etÂal. British Journal of Haematology, 2016, 175, 347-349.	2.5	3
190	Where thereâ€™s a will, thereâ€™s a way: establishing hematopoietic stem cell transplantation in Myanmar. Blood Advances, 2017, 1, 65-69.	5.2	3
191	Evaluation of nonneutralizing antibodies against factor VIII in severe haemophilia A patients from India. Blood Coagulation and Fibrinolysis, 2019, 30, 337-340.	1.0	3
192	Determination of fibrin clot growth and spatial thrombin propagation in the presence of different types of phospholipid surfaces. Platelets, 2021, 32, 1031-1037.	2.3	3
193	Outcome of iron reduction therapy in ex-thalassemics. PLoS ONE, 2021, 16, e0238793.	2.5	3
194	Very Long Term Follow-up Data of Pediatric Acute Promyelocytic Leukemia Treated with Upfront Arsenic-Trioxide Based Regimens. Blood, 2018, 132, 1400-1400.	1.4	3
195	Clinical and Molecular Characterization of Fanconi Anemia: An Indian Perspective. Blood, 2014, 124, 2938-2938.	1.4	3
196	Mesenchymal stromal stem cell therapy in advanced interstitial lung disease - Anaphylaxis and short-term follow-up. Lung India, 2015, 32, 486.	0.7	3
197	Polymorphisms in Coagulant and Inflammatory Genes Modify the Phenotype of Severe Hemophilia A and B.. Blood, 2006, 108, 1009-1009.	1.4	3
198	Polymorphism in the IFN-Î³ Gene Is Associated with Severe Acute Graft Versus Host Disease in Î² Thalassemia Major Patients Undergoing Matched Related Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 1105-1105.	1.4	3

#	Article	IF	Citations
199	Management of Relapse in Acute Promyelocytic Leukemia Treated with Upfront Arsenic Trioxide Based Regimens. Blood, 2018, 132, 666-666.	1.4	3
200	Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease. The National Medical Journal of India, 2000, 13, 188-90.	0.3	3
201	Fluorescent PCR-based gene dose analysis for detection of deletion mutations in carriers of haemophilia. Haemophilia, 2013, 19, e377-e380.	2.1	2
202	Current Issues in Hemophilia: Recognizing Clinical Heterogeneity, Replacement Therapy, and Outcome Assessment. Seminars in Thrombosis and Hemostasis, 2015, 41, 816-818.	2.7	2
203	Understanding the Molecular Basis of Heterogeneity in Induced Pluripotent Stem Cells. Cellular Reprogramming, 2015, 17, 427-440.	0.9	2
204	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 130-135.e1.	0.4	2
205	Do Bone Density, Bone Microarchitecture, and Body Composition Differ in Recipients of Allogeneic Hematopoietic Stem Cell Transplant? A Cross-Sectional Study from Southern India. Biology of Blood and Marrow Transplantation, 2020, 26, 540-545.	2.0	2
206	Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. British Journal of Haematology, 2020, 188, 930-934.	2.5	2
207	Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
208	The case for equitable haemophilia care. Lancet Haematology,the, 2021, 8, e626.	4.6	2
209	Haplo-Identical Transplants Using Post Transplant Cyclophosphamide (PTCy) Are Associated with Good Outcomes If Transplanted with Early Disease - a Single Centre Analysis from India. Blood, 2018, 132, 4652-4652.	1.4	2
210	Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate â€" Recombinant Factor VIII Fc (Eloctateâ„¢) â€" a Report from India. Blood, 2018, 132, 2494-2494.	1.4	2
211	Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates.. Blood, 2007, 110, 1998-1998.	1.4	2
212	Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.. Blood, 2009, 114, 1182-1182.	1.4	2
213	Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).. Blood, 2009, 114, 2082-2082.	1.4	2
214	Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassaemia Major Undergoing HSCT.. Blood, 2009, 114, 869-869.	1.4	2
215	Harnessing Gene Expression Profiling In Search Of New Candidate Genes For Ara-C Resistance In Acute Myeloid Leukemia. Blood, 2013, 122, 1299-1299.	1.4	2
216	A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. Blood, 2016, 128, 984-984.	1.4	2

#	Article	IF	Citations
217	Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2017, 35, 7550-7550.	1.6	2
218	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	1.4	2
219	Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning. Transplantation and Cellular Therapy, 2022, 28, 356.e1-356.e6.	1.2	2
220	Ageâ€stratified adenoâ€associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India. Journal of Medical Virology, 2022, 94, 4542-4547.	5.0	2
221	Uncertain times for research on hemophilia and allied disorders. Journal of Thrombosis and Haemostasis, 2006, 4, 680-680.	3.8	1
222	Genetic modifiers of secondary iron overload in beta thalassemia major. Blood Cells, Molecules, and Diseases, 2015, 54, 242-243.	1.4	1
223	Endocrine Challenges and Metabolic Profile in Recipients of Allogeneic Haematopoietic Stem Cell Transplant: A Cross-Sectional Study from Southern India. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 484-490.	0.6	1
224	Safety of peripheral blood stem cell harvest in children under anaesthesia in the day care setting â€“ A single centre experience. Transfusion and Apheresis Science, 2021, 60, 102962.	1.0	1
225	Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 1-9.	0.6	1
226	Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphomaâ€"A Single Center Experience. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 290-298.	0.6	1
227	Bone Marrow Transplantation for Î² Thalassemia Major: Long Term Experience from a Single Centre in India.. Blood, 2007, 110, 1106-1106.	1.4	1
228	Fludarabine and Melphalan Conditioning Regimen in Young Patients with Acute Myeloid Leukemia in CR1 Undergoing a Matched Related Allogeneic Stem Cell Transplant: A Single Center Experience.. Blood, 2007, 110, 5049-5049.	1.4	1
229	Treatment of Relapsed and Refractory Acute Myeloid Leukemia with a Salvage FLAG-IDA Chemotherapy Regimen Followed by a HLA Matched Related Allogeneic PBSC Infusion without Additional Conditioning.. Blood, 2007, 110, 5050-5050.	1.4	1
230	A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia.. Blood, 2009, 114, 1194-1194.	1.4	1
231	Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 518-518.	1.4	1
232	Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with Î²-Thalassemia Major Undergoing Allogeneic HSCT. Blood, 2011, 118, 1941-1941.	1.4	1
233	Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 2011, 118, 426-426.	1.4	1
234	NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia. Blood, 2013, 122, 4945-4945.	1.4	1

#	Article	IF	Citations
235	Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score. Blood, 2015, 126, 2620-2620.	1.4	1
236	Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition. Blood, 2016, 128, 446-446.	1.4	1
237	A Polymorphism In Interferon Gamma Gene Impacts the Extent of Joint Damage In Patients with Severe Hemophilia. Blood, 2010, 116, 546-546.	1.4	1
238	Expression Profiling Of Nuclear Hormone Receptors In Myeloid Leukemia Reveals Potential Novel Drug Targets For Combination Therapy. Blood, 2013, 122, 3855-3855.	1.4	1
239	Donor Lymphocyte Infusion in Patients with Thalassemia Major Who Have Mixed Chimerism Following Allogeneic Stem Cell Transplant. Blood, 2015, 126, 1965-1965.	1.4	1
240	Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. Blood, 2015, 126, 4386-4386.	1.4	1
241	Efficacy of Second Line Agents Dapsone & Azathioprine in Children & Adults with Immune Thrombocytopenia: Single Centre Experience from India. Blood, 2015, 126, 1064-1064.	1.4	1
242	Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies		

#	Article	IF	Citations
253	Molecular Genetics of Hereditary Prothrombin Deficiency in Indian Patients: Identification of a Novel Ala362â†'Thr (Prothrombin Vellore 1) Mutation by Conformation Sensitive Gel Electrophoresis.. Blood, 2004, 104, 1037-1037.	1.4	0
254	Cyclophosphamide Kinetics Influences Toxicity and Outcome of Bone Marrow Transplantation in Patients with Î²-Thalassemia Major.. Blood, 2004, 104, 1820-1820.	1.4	0
255	Developing an Algorithm for Monitoring Chimerism after Allogeneic Bone Marrow Transplantation - A Single Centre Experience.. Blood, 2005, 106, 5301-5301.	1.4	0
256	Durable Remissions with Single Agent As2O3 in the Treatment of Newly Diagnosed Cases of Acute Promyelocytic Leukemia: Risk Stratification within This Group and Potential Impact on Future Algorithms.. Blood, 2005, 106, 892-892.	1.4	0
257	Surveyorâ„¢ Nuclease: A New Rapid and Effective Strategy for Detection of Single Nucleotide Changes in Alpha Globin Genes.. Blood, 2005, 106, 3653-3653.	1.4	0
258	A Pilot Study of Rabbit Antithymocyte Globulin - TECELAC Combined with Cyclosporine and Prednisolone as Immunosuppressive Therapy for Severe Aplastic Anemia.. Blood, 2005, 106, 3749-3749.	1.4	0
259	Oral Prednisolone Produces a Durable Response in Pediatric Myelodysplastic Syndromes (MDS).. Blood, 2005, 106, 4906-4906.	1.4	0
260	The Role of Donor Lymphocyte Infusion (DLI) and Imatinib Mesylate in the Treatment of Relapse after Allogenic Stem Cell Transplant for Chronic Myeloid Leukemia.. Blood, 2005, 106, 5393-5393.	1.4	0
261	Fludarabine Based Conditioning for Allogeneic Transplantation in Severe Aplastic Anemia.. Blood, 2005, 106, 2029-2029.	1.4	0
262	Investigation of Underlying Reasons of Factor VIII Deficiency in Haemophilia A Patients with Undetectable Mutations in the Factor VIII Gene.. Blood, 2006, 108, 1042-1042.	1.4	0
263	A Low Intensity Protocol of Fludarabine, Busulfan and Cyclophosphamide Reduces Toxicity without Compromising Engraftment in Children Undergoing Allogeneic Bone Marrow Transplantation for Beta Thalassaemia Major.. Blood, 2006, 108, 5366-5366.	1.4	0
264	Two Mutations (1717 Tã€‰C, GP IX;124del145, GPIb beta) Occur Frequently among Patients with Bernard Soulier Syndrome in India.. Blood, 2006, 108, 1096-1096.	1.4	0
265	Il-10 Polymorphism and TGF-Î² Haplotypes Are Associated with Rejection of Graft in Children with Beta Thalassemia Major Undergoing Matched Related Bone Marrow Transplantation (BMT).. Blood, 2006, 108, 3011-3011.	1.4	0
266	Impact of Additional Cytogenetic Changes and FLT3 Mutations on the Outcome of Patients with Newly Diagnosed Acute Promyelocytic Leukaemia Treated with Single Agent Arsenic Trioxide.. Blood, 2006, 108, 2346-2346.	1.4	0
267	A New Stratification Strategy That Identifies a Subset of Class III Patients among Children with Î² Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2996-2996.	1.4	0
268	Analysis of Î² Globin Mutations in the Indian Population: Presence of Rare and Novel Mutations and Region Wise Heterogeneity.. Blood, 2007, 110, 3822-3822.	1.4	0
269	G-CSF Primed Bone Marrow Is Not Superior to Unprimed Bone Marrow as a Source of Stem Cells in HLA Matched Related Allogeneic SCT for Î² Thalassaemia Major.. Blood, 2007, 110, 5052-5052.	1.4	0
270	Molecular Analysis of WASP Gene - First Report from India.. Blood, 2007, 110, 3217-3217.	1.4	0

#	Article	IF	Citations
271	Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RARÎ±+ Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.. Blood, 2007, 110, 4366-4366.	1.4	0
272	Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide. Blood, 2008, 112, 2534-2534.	1.4	0
273	Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.. Blood, 2009, 114, 3349-3349.	1.4	0
274	Comparison of Differential Gene Expression Profiles of Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide with the Profile of An Arsenic Trioxide Resistant NB4 Cell Line.. Blood, 2009, 114, 3460-3460.	1.4	0
275	First Asia-Pacific Co-Operative Multicenter Multiple Myeloma Clinical Trial: Preliminary Results of the â€œdtZâ€/â€œDAZZLEâ€•Study.. Blood, 2009, 114, 4940-4940.	1.4	0
276	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.. Blood, 2009, 114, 846-846.	1.4	0
277	Fluorescent PCR Based Gene Dose Assessment for Detection of Deletion Mutations in the FIX Gene Among Carriers of Hemophilia B.. Blood, 2009, 114, 3486-3486.	1.4	0
278	Allogeneic Transplant In Children with Severe Aplastic Anemia â€“ Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen. Blood, 2010, 116, 3519-3519.	1.4	0
279	Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 2746-2746.	1.4	0
280	International Consortium for the Study of Clinical and Molecular Aspects of Bernard-Soulier Syndrome. Blood, 2011, 118, 707-707.	1.4	0
281	Erythroid Growth Differentiation Factor 15 and Ferroportin Expression During Gestational Iron Deficiency Anemia. Blood, 2011, 118, 5286-5286.	1.4	0
282	Response to Immunosuppressive Therapy with Antithymocyte Globulin (ATG) In Older Patients with Aplastic Anemia. Blood, 2011, 118, 4374-4374.	1.4	0
283	Improved Clinical Outcomes of High Risk Î² Thalassemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. Blood, 2011, 118, 1017-1017.	1.4	0
284	Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,. Blood, 2011, 118, 3481-3481.	1.4	0
285	Carbonyl Reductase 1 Expression and Polymorphisms Influence Daunorubicin Metabolism in AML. Blood, 2011, 118, 2484-2484.	1.4	0
286	Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data. Blood, 2011, 118, 947-947.	1.4	0
287	Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy. Blood, 2011, 118, 941-941.	1.4	0
288	RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.. Blood, 2012, 120, 2785-2785.	1.4	0

#	Article	IF	Citations
289	A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA). Blood, 2012, 120, 4199-4199.	1.4	0
290	Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors. Blood, 2012, 120, 3380-3380.	1.4	0
291	Targeted Modifications in Adeno-Associated Virus Serotype (AAV)- 8 Capsid Improves Its Hepatic Gene Transfer Efficiency in Vivo. Blood, 2012, 120, 2045-2045.	1.4	0
292	Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients. Blood, 2012, 120, 3607-3607.	1.4	0
293	ABC Transporter Expression in Acute Myeloid Leukemia: Association with in Vitro Cytotoxicity and Prognostic Markers. Blood, 2012, 120, 1438-1438.	1.4	0
294	Genetic Diagnosis of Inherited Bleeding Disorders in 1250 Probands From India: A Single Centre Experience. Blood, 2012, 120, 1127-1127.	1.4	0
295	High Expression of p53 and Growth Differentiation Factor-15 in Beta-Thalassemia.. Blood, 2012, 120, 2130-2130.	1.4	0
296	Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission. Blood, 2012, 120, 3552-3552.	1.4	0
297	Molecular and Functional Characterization of Two Novel Missense Mutations in Iron Transport Protein Causing Hypochromic Microcytic Anemia and Hemosiderosis. Blood, 2012, 120, 3202-3202.	1.4	0
298	Delay In Onset Of First Transfusion and Increased Risk Of Graft Rejection In Î² Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant. Blood, 2013, 122, 701-701.	1.4	0
299	Clinical Profile and Outcome Of Patients With Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant For Î² Thalassemia Major. Blood, 2013, 122, 4546-4546.	1.4	0
300	Molecular Basis Of (ÎÎ²)0 Thalassaemia and HPFH In Indian Population and The Role Of Non-Coding Transcripts In Increased Foetal Hemoglobin In Adults. Blood, 2013, 122, 3446-3446.	1.4	0
301	Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60â„¢) In Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3280-3280.	1.4	0
302	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. Blood, 2014, 124, 902-902.	1.4	0
303	Proteasome Activity Is Dispensable for the Degradation of PML-RARÎ±: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia. Blood, 2014, 124, 3741-3741.	1.4	0
304	Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate. Blood, 2014, 124, 1504-1504.	1.4	0
305	The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation â€“ a Phase II Study. Blood, 2014, 124, 2455-2455.	1.4	0
306	Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India. Blood, 2014, 124, 2462-2462.	1.4	0

#	Article	IF	Citations
307	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3884-3884.	1.4	0
308	Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk. Blood, 2015, 126, 3758-3758.	1.4	0
309	Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India. Blood, 2015, 126, 3219-3219.	1.4	0
310	Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India. Blood, 2015, 126, 3732-3732.	1.4	0
311	Long Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Beta Thalassemia Major. Blood, 2016, 128, 4606-4606.	1.4	0
312	Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants. Blood, 2016, 128, 3406-3406.	1.4	0
313	Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen. Blood, 2016, 128, 2201-2201.	1.4	0
314	Role of Pre-Transplant Cardiac and Hepatic T2* Magnetic Resonance for Risk Assessment in Patients with Thalassemia Major Undergoing an Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 2200-2200.	1.4	0
315	Iron Reduction Therapy in Ex-Thalassemics - Long Term Outcome. Blood, 2018, 132, 4591-4591.	1.4	0
316	SMALL Molecules Mediated Hematopoietic STEM and Progenitor CELLS Expansion for GENE Editing Application. Blood, 2018, 132, 5803-5803.	1.4	0
317	Targeted IV Vs Oral Busulfan in Very Young Children with Thalassemia Major Undergoing Matched Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5707-5707.	1.4	0
318	Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts. Blood, 2019, 134, 4537-4537.	1.4	0
319	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT. Blood, 2019, 134, 1977-1977.	1.4	0
320	Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning. Blood, 2021, 138, 1781-1781.	1.4	0
321	Optimization of Robust Diagnostic Strategy for Patients with Fanconi Anaemia (FA)- an Indian Perspective. Blood, 2021, 138, 2187-2187.	1.4	0
322	Ehl Factors at Lower Than Standard Dose Achieve Satisfactory Surgical Haemostatsis in Haemophilia. Blood, 2020, 136, 25-26.	1.4	0